Overview

Gender

male

Dr. Kim has taken a leadership role in Zafgen’s clinical development, including clinical and regulatory strategy, trial design and oversight of the company’s virtual clinical team. He also brings business development experience in the fields of obesity, endocrinology, diabetes and metabolism.
Dr. Kim is a board-certified endocrinologist and comes to Zafgen with more than 10 years of experience in the biotech and medical technology industries.

Prior to joining Zafgen, Dr. Kim held multiple senior-level clinical and corporate affairs positions at Orexigen Therapeutics, a biopharmaceutical company focused on the treatment of obesity, including senior vice president, head of obesity/metabolic diseases; senior vice president, corporate development; and senior vice president, medical affairs and communications.

Prior to Orexigen, he was chief medical officer and vice president of medical affairs at EnteroMedics, Inc., where he oversaw all aspects of clinical affairs and successfully implemented an initial public offering as part of the executive team in 2007.

Previously, he spent seven years in positions of increasing responsibility at Amylin Pharmaceuticals, Inc., most recently as executive director, corporate strategy, where he managed corporate and business strategic planning spanning all commercial products, developmental drug candidates, corporate alliance partnership and manufacturing support. While at Amylin, Dr. Kim was also the lead physician for exenatide (BYETTA®), an FDA-approved therapy for type 2 diabetes, where he directed Phase 2 through 4 development and commercialization. Currently, Dr. Kim is an assistant professor of medicine, division of endocrinology/metabolism, at the University of California, San Diego (UCSD) School of Medicine.

He holds an M.D. from the University of Health Sciences, The Chicago Medical School, an M.B.A from UCSD Rady School of Management and a B.S. in biology from the University of California at Los Angeles.